- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01285453
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors
December 6, 2020 updated by: Novartis Pharmaceuticals
A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination With Docetaxel in Japanese Patients With Advanced or Recurrent Solid Tumors
This study will assess the tolerability of combination therapy with ASA404 and docetaxel in Japanese patients with advanced or recurrent solid tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan
- Novartis Investigative Site
-
Osaka, Japan
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with confirmed solid tumors whose disease has progressed or recurred after treatment at lease one therapy, except docetaxel
- WHO Performance Status of 0-1
Exclusion Criteria:
- Patients having symptomatic CNS tumor/metastasis and requiring treatment
- Patients who have received prior therapy with ASA404 or other vascular disrupting agents
- Patients with systolic BP > 160mmHg and/or diastolic BP > 90mmHg
- Patients with fluid retention
- Patients with any one of cardiotoxicities
- Concomitant use of drugs with a risk of prolonging the QT interval
- Known allergy or hypersensitivity to taxane or polysorbate 80
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASA404
|
Other Names:
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
January 26, 2011
First Submitted That Met QC Criteria
January 26, 2011
First Posted (Estimate)
January 28, 2011
Study Record Updates
Last Update Posted (Actual)
December 9, 2020
Last Update Submitted That Met QC Criteria
December 6, 2020
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASA404A1102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced or Recurrent Solid Tumors
-
Ono Pharmaceutical Co. LtdCompletedAdvanced Solid Tumors | Recurrent Solid TumorsKorea, Republic of
-
Ono Pharmaceutical Co. LtdCompletedAdvanced Solid Tumors | Recurrent Solid TumorsKorea, Republic of
-
Beijng Immunoah Pharma Tech Co., Ltd.RecruitingRecurrent or Metastatic, Advanced Solid TumorsChina
-
Genentech, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid Tumors | Recurrent Solid TumorsAustralia, United States
-
National Cancer Center, JapanEisai Co., Ltd.Active, not recruitingAdvanced or Recurrent Solid Tumors | FGFR Gene AlterationsJapan
-
Suzhou Kanova Biopharmaceutical Co., LTDNot yet recruitingAdvanced or Metastatic Solid Tumors
-
Parthenon Therapeutics, Inc.RecruitingAdvanced or Metastatic Solid TumorsUnited States
-
PharmAbcineMerck Sharp & Dohme LLC; Novotech (Australia) Pty LimitedNot yet recruitingAdvanced or Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Completed
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
Clinical Trials on vadimezan
-
University of GlasgowCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited Kingdom
-
Novartis PharmaceuticalsTerminated
-
Novartis PharmaceuticalsTerminatedHistologically-proven and Radiologically-confirmed Solid TumorsItaly, New Zealand
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsTerminatedMetastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal FunctionBelgium
-
Novartis PharmaceuticalsTerminated
-
Antisoma ResearchCompletedProstate CancerUnited States
-
Novartis PharmaceuticalsTerminated
-
Swiss Group for Clinical Cancer ResearchCompleted
-
Hoosier Cancer Research NetworkNovartis PharmaceuticalsWithdrawnUrothelial Carcinoma